Promise

Promise Bio is an early-stage precision medicine and tech-bio company focused on transforming the treatment of immune-mediated and autoimmune diseases. Spun out of the Weizmann Institute of Science and backed by AION Labs, the company leverages its proprietary PROMISE (Protein Modification Integrated Search Engine) platform to perform unbiased, large-scale epiproteomic analysis. By combining artificial intelligence with mass spectrometry, Promise Bio detects dozens of post-translational modifications (PTMs) simultaneously from a single blood sample without requiring chemical enrichment. This high-resolution view of the proteome enables the identification of novel drug targets, prediction of patient treatment responses, and stratification of patients for clinical trials, ultimately aiming to eliminate the trial-and-error approach in autoimmune therapy.